Protein kinase C inhibitor, AEB-071, acts complementarily with cyclosporine to prevent islet rejection in rats

Transplantation

Volumn 87, Issue 1, 2009, Pages 59-65

  Merani, Shaheed ^a   Pawlick, Rena L ^a   Edgar, Ryan L ^a   Toso, Christian ^a   Emamaullee, Juliet ^a   Anderson, Colin C ^a   Shapiro, A M James ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Diabetes; Immunosuppression; Islet transplant; Protein kinase C; Rat

Indexed keywords

ABATACEPT; CYCLOSPORIN A; GAMMA INTERFERON; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SOTRASTAURIN; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR;

ALLOIMMUNITY; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL INFILTRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GRAFT REJECTION; IMMUNOMODULATION; IN VIVO STUDY; INSULIN RELEASE; MALE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RAT; STREPTOZOCIN DIABETES; SURVIVAL TIME; ANIMAL; AUTOIMMUNITY; DRUG ANTAGONISM; DRUG POTENTIATION; IMMUNOLOGY; METABOLISM; PANCREAS ISLET; PANCREAS ISLET TRANSPLANTATION; PHYSIOLOGY; TIME;

ANIMALS; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYCLOSPORINE; DRUG SYNERGISM; FEMALE; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; INSULIN; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; RATS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 58949095664     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31819198b4     Document Type: Article

References (18)

1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free im-munosuppressive regimen. N Engl J Med 2000; 343: 230.
2. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318.
3. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060.
4. Larsen JL, Bennett RG, Burkman T, et al. Tacrolimus and sirolimus cause insulin resistance in normal sprague dawley rats. Transplantation 2006; 82: 466.
5. Paty BW, Harmon JS, Marsh CL, et al. Inhibitory effects of immuno-suppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. Transplantation 2002; 73: 353.
6. Evenou J-P, Brinkmann V, Towbin H, et al. Enzymatic cellular characterization of NVP-AEB071 (AEB), a novel selective protein kinase C (PKC) inhibitor that blocks early T cell activation, and its use to define the role of PKC in T cells. Am J Transplant 2006; 6(suppl 2): 1026.
7. Evenou J-P, Thuille N, Cottens S, et al. NVP-AEB071 (AEB), a novel protein kinase C inhibitor, abrogates early mouse T cell activation without affecting activation induced cell death. Am J Transplant 2006; 6(suppl 2): 1029.
8. Hayashi K, Altman A. Protein kinase C theta (PKCtheta): A key player in T cell life and death. Pharmacol Res 2007; 55: 537.
9. Sun Z, Arendt CW, Ellmeier W, et al. PKC-theta is required for TCR-induced NF-kappaB activationin mature but not immature T lymphocytes. Nature 2000; 404: 402.
10. Werlen G, Jacinto E, Xia Y, et al. Calcineurin preferentially synergizes with PKC-theta to activate JNK and IL-2 promoter in T lymphocytes. Embo J 1998; 17: 3101.
11. Ghaffari-Tabrizi N, Bauer B, Villunger A, et al. Protein kinase Ctheta, a selective upstream regulator of JNK/SAPK and IL-2 promoter activation in Jurkat T cells. Eur J Immunol 1999; 29: 132.
12. Shapiro AM, Hao E, Rajotte RV, et al. High yield of rodent islets with intraductal collagenase and stationary digestion - A comparison with standard technique. Cell Transplant 1996; 5: 631.
13. Zeller W, Weber H, Panoussis B, et al. Refinement of blood sampling from the sublingual vein of rats. Lab Anim 1998; 32: 369.
14. Li S, Salgar SK, Thanikachalam M, et al. CTLA4-Ig-based conditioning regimen to induce tolerance to cardiac allografts. J Surg Res 2006; 136: 238.
15. Onodera K, Chandraker A, Schaub M, et al. CD28-B7 T cell costimu-latory blockade by CTLA4Ig in sensitized rat recipients: Induction of transplantation tolerance in association with depressed cell-mediated and humoral immune responses. J Immunol 1997; 159: 1711.
16. Shiraishi T, Yasunami Y, Takehara M, et al. Prevention of acute lung allograft rejection in rat by CTLA4Ig. Am J Transplant 2002; 2: 223.
17. Fotiadis C, Xekouki P, Papalois AE, et al. Effects of mycophenolate mofetil vs cyclosporine administration on graft survival and function after islet allotransplantation in diabetic rats. World J Gastroenterol 2005; 11: 2733.
18. Xekouki P, Papalois A, Fotiadis C, et al. In vivo test of two low doses of mycophenolate mofetilinanexperimental modelofislet allotransplantation. Transplant Proc 2002; 34: 1446.